| (Values in U.S. Thousands) | Mar, 2026 | Dec, 2025 | Sep, 2025 | Jun, 2025 | Mar, 2025 |
| Sales | 246,090 | 203,330 | 156,720 | 452,050 | 131,610 |
| Sales Growth | +21.03% | +29.74% | -65.33% | +243.48% | -41.91% |
| Net Income | -92,530 | -229,390 | -128,610 | 123,550 | -146,940 |
| Net Income Growth | +59.66% | -78.36% | -204.10% | +184.08% | -40.81% |
Ionis Pharmaceuticals (IONS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Ionis Pharmaceuticals discovers/develops RNA-targeted therapeutics using its proprietary antisense oligonucleotide technology. Its antisense medicines have been developed/are being developed to treat neurological, cardiovascular and specialty rare diseases.
Fiscal Year End Date: 12/31